Aspo reports Q2 results on Aug 18. Telko and Leipurin are on a steady track to improve more after la...
Endomines delivered a strong performance in H1, despite a slight shortfall relative to our profitabi...
Redeye returns with positive estimate revisions following Bredband2's report that all in all, was so...
We lower 2025E adjusted EBIT by 10% yet keep 2026E-27E adjusted EBIT largely intact (+2%), as we fin...
Återhämtningen av marginalen går fortare än väntat och omsättningen är på spåret.
- Solid top-line and normalising costs; Q2 EBITA +15% vs.
Redeye comments on Bredband2’s Q2 report which posted marginally stronger performance across the boa...
Relais Q2 adjusted EBITA of EUR 7.6m was up 3% y/y and came 2% above LSEG Data & Analytics consensus...
Dovre’s project challenges have been extended, but Sweden and Finland should offer more opportunitie...
Redeye provides an update on Scandinavian ChemoTech following the Q2 2025 report.
Redeye comments on the SEK2.2m milestone bonus payment received for a game under a work-for-hire agr...
Redeye is encouraged by the NTAP for CERAMENT G used in trauma, as it aids in the company’s early-st...
EBIT -9% vs cons, -15% vs ABGSC Order backlog +25%, organic growth +43% y-o-y We expect limited esti...
Margin upside building into H2 We cut EBITDA by 9-4% for '25e-'27e Trading at ~22x '26e EV/EBITDA F...
Alisa Bank’s H1 was slightly weaker than expected. We remain cautious on near-term development but n...
